BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Other analysts have also issued reports about the stock. Raymond James Financial reduced their price target on shares of BridgeBio Oncology Therapeutics from $24.00 to $22.00 and set an “outperform” rating for the company in a research report on Wednesday. Stifel Nicolaus lowered their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday. Finally, Canaccord Genuity Group decreased their target price on shares of BridgeBio Oncology Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.88.

BridgeBio Oncology Therapeutics Trading Down 10.3%

Shares of BBOT stock opened at $4.95 on Friday. BridgeBio Oncology Therapeutics has a 1-year low of $4.90 and a 1-year high of $14.87. The company has a market capitalization of $396.84 million, a price-to-earnings ratio of -1.79 and a beta of 0.38. The stock’s fifty day simple moving average is $8.66 and its 200-day simple moving average is $8.67.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that BridgeBio Oncology Therapeutics will post -2.79 EPS for the current year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Several institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. boosted its position in shares of BridgeBio Oncology Therapeutics by 1,213.8% in the second quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock valued at $5,334,000 after acquiring an additional 646,718 shares during the period. Armistice Capital LLC grew its stake in shares of BridgeBio Oncology Therapeutics by 142.7% in the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after acquiring an additional 588,000 shares during the last quarter. Laurion Capital Management LP increased its position in BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after acquiring an additional 419,138 shares during the period. Catalio Capital Management LP bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth $5,142,000. Finally, Paradigm Biocapital Advisors LP raised its stake in BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after purchasing an additional 395,608 shares during the last quarter. 54.89% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Oncology Therapeutics News Summary

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: JPMorgan maintained an “overweight” rating while lowering its price target from $25 to $23. Even after the reduction, the target implies substantial potential upside from the recent $4.95 share price. JPMorgan price target update
• Positive Sentiment: Wedbush reiterated its “outperform” rating, signaling that it continues to see meaningful value in BridgeBio Oncology Therapeutics despite the recent selloff. Wedbush reiterates outperform rating
• Neutral Sentiment: The company is narrowing its KRAS strategy. BridgeBio Oncology Therapeutics is focusing its development efforts on a more targeted subset of KRAS-related cancer opportunities. The approach could improve capital allocation and differentiation, but it also increases dependence on a narrower group of clinical programs. BridgeBio Oncology Therapeutics bets on a narrower KRAS strategy
• Negative Sentiment: Analyst downgrades drove renewed selling. Leerink Partners issued a pessimistic forecast, while Wall Street Zen lowered the stock to “strong sell.” These actions have weakened investor sentiment toward the company’s valuation and clinical prospects. Leerink Partners forecast Wall Street Zen strong sell downgrade
• Negative Sentiment: BBOT reached a new 52-week low following the downgrades, reinforcing technical and momentum concerns. The stock’s decline of more than 10% in the recent session occurred alongside unusually heavy trading volume. BridgeBio Oncology Therapeutics new 52-week low Why BBOT stock declined

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.